reconsideration of gefitinib in egfr-mutant nsclc
Published 9 years ago • 630 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:30
dr. drilon on tepotinib and gefitinib in met egfr-mutant nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
2:10
role of gefitinib in egrf-mutant disease
-
4:09
frontline afatinib in egfr-mutant nsclc
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
3:35
novel egfr inhibitor combinations for nsclc
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
2:02
evolutions in the treatment of egfr-mutated nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:15
dr. aggarwal on triplet therapy in egfr-mutant lung cancer
-
5:00
options for up-front therapy in egfr-mutant nsclc
-
3:24
sequencing of therapies in egfr-mutant nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:58
dr. bazhenova on sequencing beyond progression in egfr-mutant nsclc
-
2:50
sequencing with osimertinib in egfr-mutated nsclc